Enoblituzumab
Based on 2 publication(s) in Google Scholar
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.16%
- CAS. Nr.: 1353485-38-7
- Molecular Weight:146.1 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
B7-H3/CD276
In Vitro
Enoblituzumab interacts with B7-H3 and causes strong antibody-dependent cellular cytotoxicity (ADCC) against a wide spectrum of cancer cells[2].
Enoblituzumab (0.01 ng/mL-10 mg/mL) mediates antibody-dependent cellular cytotoxicity (ADCC) against A498 cells with cynomolgus monkey peripheral blood mononuclear cells (PBMCs)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mCD16-/-hCD16A+ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)[3]
-
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg
-
Administration:Intravenous injection; once weekly; 5 weeks
-
Result:Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.
Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD276/B7-H3 Protein, Human can bind Enoblituzumab. The EC50 for this effect is 2.502 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells with Enoblituzumab (HY-P9966, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Loaded Enoblituzumab on Protein A Chip, can bind CD276/B7-H3 Protein, Human (HEK293, His, HY-P7327) with an affinity constant of 1.27E-07 M as determined in SPR assay.
Product Details
-
CAS. Nr. 1353485-38-7
-
Accession Q5ZPR3
-
Synonyms MGA271
-
Molecular Weight 146.1 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
99.16%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
pH/ROS-Responsive Injectable Hydrogel Co-Loaded with B7-H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy. [Abstract]2026 Apr;13(20):e15431. PMID: 41684277 -
Reinheit & Dokumentation
Verweise
[1]. Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. [Content Brief]
[3]. Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)